Detailed Information

Cited 43 time in webofscience Cited 46 time in scopus
Metadata Downloads

Treatment Outcomes Between Concurrent Chemoradiotherapy and Combination of Surgery, Radiotherapy, and/or Chemotherapy in Stage III and IV Maxillary Sinus Cancer: Multi-Institutional Retrospective Analysis

Authors
Kang, Jung HunCho, Su HeeKim, Jin PyeongKang, Ki MunCho, Kyu SupKim, WontaekSeol, Young MiLee, SueePark, Heon SooHur, Won JooChoi, Young-JinOh, Sung Yong
Issue Date
Jul-2012
Publisher
W B SAUNDERS CO-ELSEVIER INC
Citation
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, v.70, no.7, pp 1717 - 1723
Pages
7
Indexed
SCI
SCIE
SCOPUS
Journal Title
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
Volume
70
Number
7
Start Page
1717
End Page
1723
URI
https://scholarworks.gnu.ac.kr/handle/sw.gnu/22117
DOI
10.1016/j.joms.2011.06.221
ISSN
0278-2391
1531-5053
Abstract
Purpose: The incidence of maxillary sinus cancer (MSC) is extremely rare, representing less than 1% of all cancers. Because of its rarity, the management of locally advanced MSC is a challenging issue. The objective of the present study was to retrospectively compare the efficacy of 2 traditional treatment strategies, concurrent chemoradiotherapy (CCRT) versus combination of surgery and radiotherapy and/or chemotherapy (SRCT) in MSC. Patients and Methods: From 1989 to 2010, 65 patients with histologically confirmed stage III or IVA/IVB were retrospectively analyzed. Results: The median age of our subjects was 60 years (range 36 to 81). The present study involved 18 women (27.7%) and 47 men (72.3%). Of the 65 patients, 52 (80.0%) had squamous cell carcinoma. The TNM stage was stage III, as determined by the American Joint Committee on Cancer, 6th edition, in 27 patients (41.5%). Stage IVA or IVB was observed in 38 patients (58.5%). Of the 65 patients, 41 underwent treatment. Of these 41 patients, 26 and 15 patients underwent SRCT and CCRT, respectively. During the 75.6 months (range 6.4 to 249.4) of median follow-up, the median progression- free survival duration was 45.1 months (95% confidence interval 0.0 to 142.7). The 5-year overall survival rate was 64.8%. However, the patients who had undergone surgery had better progression-free survival (hazard ratio 2.363, 95% confidence interval 1.098 to 5.085, P = .028) and overall survival (hazard ratio 4.989, 95% confidence interval 1.646 to 15.118, P = .004). The SRCT group had a better progression- free survival (P = .043) and overall survival (P = .029) duration than did the CCRT group. Conclusion: SRCT might be superior to CCRT for locally advanced MSC. Additional studies comparing the treatment outcomes of CCRT with SRCT are warranted. (C) 2012 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 70:1717-1723, 2012
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medicine > Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kang, Jung Hun photo

Kang, Jung Hun
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE